Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc and keeping the price target at $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rami Katkhuda has given his Buy rating due to a combination of factors, including his conviction that the LUCIDITY Phase III study for avexitide in post-bariatric hypoglycemia (PBH) is meaningfully de-risked. His view is supported by strong mechanistic rationale for GLP-1 antagonism, consistent efficacy signals across five prior studies, and a Phase IIb trial that showed a sizable reduction in clinically significant hypoglycemic events relative to what LUCIDITY is powered to detect.
Katkhuda also highlights the substantial unmet need in PBH, a serious and increasingly recognized complication affecting an estimated 160,000 patients in the U.S. alone. With topline data expected in Q3 2026 and Amylyx already working on the regulatory package and commercial build-out for a potential 2027 launch, he sees an attractive market opportunity and a well-capitalized company positioned to translate positive data into commercial value for shareholders.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 32.0% and a 53.85% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Disc Medicine.
In another report released on March 25, Mizuho Securities also reiterated a Buy rating on the stock with a $19.00 price target.